Indication
X-linked retinoschisis
5 clinical trials
6 products
Clinical trial
A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Tolerability of ATSN-201 Gene Therapy in Male Subjects With RS1-Associated X-linked RetinoschisisStatus: Recruiting, Estimated PCD: 2025-10-01
Product
ATSN-201Clinical trial
Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of ZM-01 in 3-18 Year-old Male Subjects With X-linked RetinoschisisStatus: Recruiting, Estimated PCD: 2023-10-31
Product
ZM-01-HProduct
ZM-01-LClinical trial
Clinical Study on the Safety and Efficacy of JWK002 Injection Administered as a Single Subretinal Injection in Subjects With X-linked RetinoschisisStatus: Recruiting, Estimated PCD: 2026-12-30
Product
JWK002Clinical trial
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked RetinoschisisStatus: Completed, Estimated PCD: 2019-04-01
Product
rAAV2tYF-CB-hRS1Clinical trial
An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX103 in Patients With X-Linked Retinoschisis (XLRS)Status: Recruiting, Estimated PCD: 2024-08-01
Product
LX103